

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

NOTE: This special called meeting will be held virtually via Zoom webinar.

Thursday, November 17, 2022
1:00 P.M. to 4:00 P.M. (Eastern)

Access Information

Smartphone/Web	Dial-In
https://magellanhealth.zoom.us/j/98107680594 Webinar ID: 981 0768 0594 Password: 557792	+1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll) Webinar ID: 981 0768 0594 Passcode: 557792

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
 - a. Approval of September 2022 Meeting Minutes
- IV. New Business**
 - a. New Products to Market to be reviewed as single products:
 - i. Ztalmy[®] (Anticonvulsants: Second Generation)
 - ii. Zoryve[™] (Topical Psoriasis Agents)
 - iii. Vivjoa[™] (Antifungals: Oral)
 - iv. Sotyktu[™] (Cytokine and CAM Antagonists)
 - b. Existing products to be reviewed as single products:
 - i. Tyvaso[®] Tyvaso DPI[™] (Pulmonary Arterial Hypertension (PAH) Agents)
- V. Therapeutic Classes with Recommended Changes**
 - a. Anticonvulsants: First Generation
 - b. Topical Antifungal Agents
 - c. Anti-Emetics: Other
 - d. Topical Antiviral Agents
 - e. GI Motility Agents
 - f. Immunomodulators, Atopic Dermatitis
 - g. Multiple Sclerosis Agents
 - h. Topical Steroids
- VI. Consent Agenda**
 - a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"> • Acne Agents, Oral • Acne Agents, Topical • Antibiotics, Topical • Anticholinergics/Antispasmodics • Antidiarrheals • Antiemetics & Antivertigo Agents <ul style="list-style-type: none"> ○ Oral Anti-Emetics: 5-HT₃ Antagonists ○ Oral Anti-Emetics: NK-1 Antagonists ○ Oral Anti-Emetics: Δ-9-THC Derivatives • Antiparasitic, Topical • Antipsoriatic, Oral • Antipsoriatics, Topical • Anti-Ulcer Protectants • Bile Salts • Cytokine and CAM Antagonists • Histamine II Receptor Blockers (H₂ Receptor Antagonists) • H. pylori Treatment • Immunomodulators, Asthma • Immunosuppressives, Oral (Immunosuppressants) • Laxatives and Cathartics • Ophthalmics, Allergic Conjunctivitis <ul style="list-style-type: none"> ○ Ophthalmic Antihistamines ○ Ophthalmic Mast Cells Stabilizers 	<ul style="list-style-type: none"> • Ophthalmics, Antibiotics <ul style="list-style-type: none"> ○ Ophthalmic Quinolones ○ Ophthalmic Antibiotics, Non-Quinolones • Ophthalmics, Antibiotics-Steroid Combinations • Ophthalmics, Anti-inflammatories • Ophthalmic NSAIDs • Ophthalmic Anti-inflammatory Steroids • Ophthalmics, Antivirals • Ophthalmics, Glaucoma Agents <ul style="list-style-type: none"> ○ Ophthalmic Beta Blockers ○ Ophthalmic Carbonic Anhydrase Inhibitors ○ Ophthalmic Combinations for Glaucoma ○ Ophthalmic Prostaglandin Agonists ○ Ophthalmic Sympathomimetics ○ Ophthalmic Glaucoma Agents, Other • Ophthalmic Immunomodulators • Ophthalmics, Mydriatics & Mydriatic Combinations • Ophthalmic Vasoconstrictors • Otic Antibiotics • Otic Anesthetic and Anti-Inflammatories • Proton Pump Inhibitors • Rosacea Agents, Topical • Spinal Muscular Atrophy • Ulcerative Colitis Agents
---	--

VII. Adjournment

- a. Schedule of Upcoming Meetings
 - i. **January 19, 2023**
 - ii. **March 16, 2023**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to <https://kyportal.magellanmedicaid.com/provider/public/home.xhtml>.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at: <https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.